Biomerica (BMRA) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

BMRA · Stock Price

USD 2.20-1.38 (-38.55%)

Market Cap: $6.7M

Historical price data

Market Cap: $6.7MFounded: 1971HQ: Irvine, United States

Sector Ranking#143 in Diagnostics & Precision Medicine

Overview

Biomerica is a publicly traded diagnostics company with a 40+ year history, specializing in immunoassay-based tests for chronic conditions. Its flagship innovation is the inFoods® IBS program, a diagnostic-guided therapy designed to identify food triggers for Irritable Bowel Syndrome patients. The company's strategy leverages its FDA and CE-certified manufacturing capabilities to both commercialize proprietary products and provide contract services, aiming to capture value in the large, underserved IBS market.

GastrointestinalInflammatory Diseases

Technology Platform

Immunoassay-based diagnostic platform specializing in Enzyme-Linked Immunosorbent Assay (ELISA) and rapid lateral flow tests, applied to chronic disease detection and personalized diagnostic-guided therapies like food intolerance testing.

Funding History

2

Total raised:$10.5M

PIPE$6.5MUndisclosedNov 15, 2021

PIPE$4MUndisclosedMay 15, 2019

Opportunities

The primary opportunity is the multi-hundred million dollar U.S.

market for a personalized diagnostic-guided therapy for Irritable Bowel Syndrome (IBS), affecting over 40 million Americans.

Success with inFoods® IBS could also create a platform for addressing other IgG-mediated inflammatory conditions, significantly expanding the addressable market.

Risk Factors

Key risks include the failure of the pivotal clinical trial for inFoods® IBS, regulatory rejection or delay by the FDA, and the inability to secure adequate insurance reimbursement upon potential approval.

The company also faces financial risk due to its limited cash runway and likely need for dilutive financing.

Competitive Landscape

In the broad IVD market, Biomerica competes with giants like Abbott and Roche on cost and distribution. For its lead inFoods® IBS program, it faces competition from less rigorously validated food sensitivity tests (LDTs/DTC) and the entrenched standard of empirical dietary management. Its pursuit of FDA PMA is a key differentiator aiming for superior clinical validation.